

## Special Issue

# Advances in TNBC: New Markers for Innovative Treatments

### Message from the Guest Editor

Triple-negative breast cancer (TNBC) is a breast cancer subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and the absence of type 2 epidermal growth factor receptor (HER-2) overexpression. This feature makes TNBC a hard-to-treat tumor. To date, chemotherapy is the first-line treatment, but many TNBCs only partially respond to it. Many molecules, such as EGFR, PI3K, PARP, MEK, and histone deacetylase (HDAC), are mutated or hyperactivated, while others, for instance, AR and ER $\beta$ , control growth and spreading, thereby all representing an attractive target to develop effective therapies in TNBC. Another weakness of TNBC is the presence of many immune cells, thereby immunotherapy represents another fascinating weapon to treat this incurable cancer. This Special Issue aims to update the knowledge on TNBC and give new ideas for studying, developing, and testing new drugs. I would like to invite you to contribute to this Special Issue with your research articles and reviews that include but are not limited to the following topics: molecular targets, signaling pathways, miRs, the role of epigenetics, new drugs, and targeted treatments in TNBC.

---

### Guest Editor

Dr. Pia Giovannelli

Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy

---

### Deadline for manuscript submissions

closed (31 October 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/166462](https://mdpi.com/si/166462)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)